NUC-3373 Synthesis Through Protected-Intermediate Crystallization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for preparing 5-fluoro-2′-deoxyuridine-5′-O-[1-naphthyl (benzoxy-L-alaninyl)] phosphate (NUC-3373) result in unstable compounds, particularly due to the mixture of diastereoisomers, which affects long-term storage and stability.
Innovation Solution
A process involving crystallization of the protected species followed by deprotection is used to enhance stability, utilizing specific solvents and anti-solvents like ethanol, acetonitrile, and hexane to achieve diastereomerically pure NUC-3373.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If existing methods are used to prepare NUC-3373, then the compound can be produced, but the compound is unstable and forms a mixture of diastereoisomers affecting long-term storage
Solution Approach 1:
The patent applies preliminary action by crystallizing the protected species (Ic) before deprotection to NUC-3373. This preliminary crystallization step establishes a pure diastereoisomeric form early in the synthesis process, which then maintains stability throughout subsequent deprotection and storage. The crystallization occurs at a defined stage (protected intermediate) rather than attempting to purify the final unstable product.
Solution Approach 2:
The patent utilizes parameter changes by controlling crystallization conditions (solvent selection, temperature, concentration) to selectively obtain one diastereoisomer of the protected species. By changing physical parameters during crystallization, the process achieves high diastereoisomeric purity (>85%) that is then preserved through deprotection to give stable NUC-3373.
2Stability of the object's composition
If the protected species is crystallized before deprotection, then stability and purity are improved, but additional process steps are required
Solution Approach 1:
The patent uses the protected species (Ic) as an intermediary form that can be crystallized and stored. This intermediary serves as a stable, purifiable intermediate that facilitates the overall process by allowing separation of the crystallization/purification step from the final deprotection step, thereby improving overall stability without excessive complexity.
3Duration of action of stationary object
If diastereomerically pure NUC-3373 is obtained, then long-term storage is enabled, but purification processes become more complex
Solution Approach 1:
The patent performs preliminary purification by crystallizing the protected species (Ic) before deprotection to NUC-3373. This preliminary action achieves diastereoisomeric separation at the intermediate stage, which is easier than purifying the final product. The purified intermediate then converts to stable NUC-3373 without requiring further complex purification steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process results in NUC-3373 with increased stability, allowing for long-term storage and improved purity, with diastereoisomeric purity greater than 85%, suitable for pharmaceutical formulations.
Implementation Method 1
crystallising the compound of formula (Ic) from one or more solvents
Implementation Method 2
removing the protecting group P1 from the compound of formula (Ic) to provide NUC-3373 (I)
Data Source
AI summary
This invention relates to a novel process for the preparation of 5-fluoro-2′-deoxyuridine-5′—O-[1-naphthyl (benzoxy-L-alaninyl)] phosphate (NUC-3373) and derivatives thereof. The NUC-3373 made according to this process is more stable than NUC-3373 made according to alternative processes.